How to buy Connect Biopharma (CNTB) stock

Connect Biopharma Holdings Limited is a biotechnology business based in the US. Connect Biopharma shares (CNTB) are listed on the NASDAQ and all prices are listed in US Dollars. Connect Biopharma employs 62 staff and has a market cap (total outstanding shares value) of 0.00.

Connect Biopharma stock price (NASDAQ: CNTB)

Use our graph to track the performance of CNTB stocks over time.

Connect Biopharma shares at a glance

• Key figures

Information last updated 2021-07-15.

52-week range	$14.02 - $24.10
50-day moving average	$18.28
200-day moving average	$17.26
Wall St. target price	$29.63
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Connect Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Connect Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Connect Biopharma Holdings Limited by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Connect Biopharma financials

Gross profit TTM	$0
Return on assets TTM	-14.75%
Return on equity TTM	-9999999%
Profit margin	0%
Book value	N/A
Market capitalisation	$1.3 billion

TTM: trailing 12 months

Shorting Connect Biopharma shares

There are currently 774,912 Connect Biopharma shares held short by investors – that's known as Connect Biopharma's "short interest". This figure is 2% up from 759,690 last month.

There are a few different ways that this level of interest in shorting Connect Biopharma shares can be evaluated.

Connect Biopharma's "short interest ratio" (SIR)

Connect Biopharma's "short interest ratio" (SIR) is the quantity of Connect Biopharma shares currently shorted divided by the average quantity of Connect Biopharma shares traded daily (recently around 50384.395318596). Connect Biopharma's SIR currently stands at 15.38. In other words for every 100,000 Connect Biopharma shares traded daily on the market, roughly 15380 shares are currently held short.

To gain some more context, you can compare Connect Biopharma's short interest ratio against those of similar companies.

• Gilead Sciences (GILD.US): 3.52
• Vertex Pharmaceuticals Incorporated (VRTX.US): 1.3
• Amgen (AMGN.US): 3.8

However Connect Biopharma's short interest can also be evaluated against the total number of Connect Biopharma shares, or, against the total number of tradable Connect Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Connect Biopharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Connect Biopharma shares in existence, roughly 10 shares are currently held short) or 0.1402% of the tradable shares (for every 100,000 tradable Connect Biopharma shares, roughly 140 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Connect Biopharma.

Find out more about how you can short Connect Biopharma stock.

Connect Biopharma share dividends

We're not expecting Connect Biopharma to pay a dividend over the next 12 months.

You may also wish to consider:

• Gilead Sciences (GILD.US) (4.02% forward annual dividend yield)
• Amgen (AMGN.US) (2.68% forward annual dividend yield)

Connect Biopharma overview

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China. .

Frequently asked questions

What percentage of Connect Biopharma is owned by institutions?
Currently 28.203% of Connect Biopharma shares are held by institutions. How many people work for Connect Biopharma?
Latest data suggests 62 work at Connect Biopharma. When does the fiscal year end for Connect Biopharma?
Connect Biopharma's fiscal year ends in December. Where is Connect Biopharma based?
Connect Biopharma's address is: East R&D Building, Taicang, China, 215400